The European Commission has opened a formal investigation into possible anticompetitive conduct by Sanofi for disparaging a competitor’s flu vaccine intended for vulnerable patient groups.
Sanofi’s ‘Efluelda’ and CSL Seqirus’s ‘Fluad’ enhanced flu vaccine are specifically designed to provide greater protection against influenza for people over 60.
The Commission claims that Sanofi pursued a misleading communication campaign targeting healthcare professionals in Germany and France, suggesting that the evidentiary basis for Fluad was weaker than for its vaccine. This contradicted the findings of the European Centre for Disease Control (ECDC) and national immunisation technical advisory groups in Germany and France.
A Sanofi spokesperson told Vital Signs that they may address the Commission’s concerns through commitments. Adding that Sanofi…
